[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:prolyl-endopeptidase-fap":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","Prolyl Endopeptidase FAP",7,[8,16,23,29,35,41,47],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04939610","A Study of 177Lu-FAP-2286 in Advanced Solid Tumors",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.824951Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07454642","AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors",[20],"Phase 1","2026-08-26T02:15:39.267524Z","2026-07-05T05:32:16.683506Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04969835","A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours",[20],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:29.397013Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06710756","Lead-212 PSV359 Therapy for Patients With Solid Tumors",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:28.400599Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT07213791","A Study of LY4337713 in Participants With FAP-Positive Solid Tumors",[20],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.120672Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT04621435","Imaging of Solid Tumors Using FAP-2286",[20],"2026-08-26T02:15:34.659160Z","2026-06-16T05:54:07.905981Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05547321","Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.",[20],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.476219Z"]